Developing Phage-Based Therapeutics for Unmet Medical Needs: The BiomX Experience

Time: 9:25 am
day: Day One


  • What is known: how phage therapeutics fit into existing regulatory frameworks
  • What is new: manufacturing challenges for pathogenic producer cell lines and product safety
  • What regulatory approaches remain to be determined: e.g. novel clinical trial approaches, long term safety, product evolution to keep in front of phage resistance